Introduction: Prostate specific antigen (PSA) screening for prostate cancer has recently been challenged due to poor sensitivity. A number of conditions elevate PSA besides prostate cancer with benign prostatic hypertrophy (BPH) being most common. The objective of this study was to assess the positive predictive value (PPV) of PSA and PSA density (PSAD) for prostate cancer risk following Holmium laser enucleation of the prostate (HoLEP).
Results: 55 patients underwent "for cause" transrectal ultrasound prostate biopsy following HoLEP. Cancer was identified in over 90% of those biopsied. Men with PSA above 1 at time of biopsy had a 94% probability of cancer detection and 80% risk of clinically significant disease. PSAD above 0.1 was associated with a 95% risk of cancer and 88% risk of clinically significant cancer. A PSA greater than 5.8 or PSAD greater than 0.17 was universally associated with biopsy proven cancer.
Conclusions: Post HoLEP PSA and PSAD have high PPV for prostate cancer risk. Thresholds for biopsy should be lower than for non-HoLEP patients. HoLEP patients with PSA above 1 or PSAD above 0.1 have higher likelihoods of harboring clinically significant disease and should undergo biopsy. Referring physicians should be aware of these significant risk shifts.
Introduction:
Prostate specific antigen (PSA) is a protein produced by both benign and malignant prostate tissue 1 . Screening for prostate cancer with PSA, in conjunction with physical examination, began in the late 1980's and resulted in subsequent stage migration and decline in prostate cancer mortality over the subsequent decades 2, 3 . Recently, the use of PSA for prostate cancer screening has been questioned due to the low positive predictive value (PPV) at any PSA threshold 2,4-6 . As such, numerous studies have investigated other biomarkers for prostate cancer such as prostate cancer antigen 3 (PCA3), kallikrein panel (4k-panel) and PSA density (PSAD) which have improved discriminative ability when combined with PSA 7, 8 .
Elevated PSA values may be caused by other conditions besides prostate cancer such as benign prostatic hypertrophy (BPH). In men with BPH, PSA is positively correlated with prostate volume 9 . Men requiring surgical intervention for BPH have a number of surgical options including transurethral resection of the prostate (TURP) and Holmium laser enucleation of the prostate (HoLEP). Historical studies suggest the benign nomenclature of BPH is not necessarily accurate as prostate cancer may be found in up to 17% of men undergoing transurethral resections 10, 11 . Moreover, these men are still at risk of developing prostate cancer in the remaining peripheral zone tissue which necessitates prostate cancer surveillance in appropriately selected men after resection. What remains unanswered is the PSA threshold after resection which should initiate further work-up. We believe that men undergoing HoLEP, given that the entirety of their transition zone is removed during the procedure, may serve as a unique model to evaluate the ability of PSA and PSAD to in detect prostate cancer in this population.
Our current study investigates the utility of PSA and PSAD in detecting prostate cancer in patients who underwent transrectal ultrasound guided (TRUS) guided biopsy following HoLEP.
Methods:
Patient Selection: After Institutional Board approval, the Indiana University BPH database was queried to identify all men with post-HoLEP PSA data from 1999-2018. Patients were stratified into two distinct categories: men who underwent TRUS guided biopsy of the prostate following HoLEP (analytical cohort) and those that did not (comparative cohort). Our primary focus was
describing outcomes of the analytical cohort. Men with a known diagnosis of prostate cancer who underwent HoLEP for LUTS were included in the analytical cohort. A total of 55 patients met criteria for the analytical cohort.
Primary Outcome: The primary outcome was the detection of prostate cancer after HoLEP. Secondary outcomes included the detection of clinically significant prostate cancer as defined as Gleason Grade Group (GGG) ≥ 2 after HoLEP. Finally, association between post-HoLEP PSA and PSA density and detection of prostate cancer post HoLEP in the analytic cohort was assessed.
PSA and PSA Density: Laboratory and imaging data were reviewed to capture PSA and prostate volume data. For both the analytic and comparative cohort, these values were obtained prior to the HoLEP and immediately after the HoLEP. Prior to HoLEP, prostatic volume estimates were most commonly obtained from transrectal ultrasound measurements. In the absence of TRUS volume measurements, cross-sectional imaging (for CT and MRI) was used to calculate volume through the following formula: 0.5 x length x width x height. For patients without imaging, physician estimate of gland size on digital rectal exam was used to approximate volume. PSA and volume estimates at each time-point were used to calculate PSA density.
For the analytic cohort, PSA and prostate volume values were collected prior to TRUS biopsy of the prostate. PSA values pre-biopsy were stratified into three groups to assess association between pre-biopsy PSA and primary and secondary endpoints. Likewise, PSA density values were stratified into three groups to similarly assess association between pre-biopsy PSAD and primary and secondary outcomes.
Statistical Analysis: Descriptive statistics were utilized to describe the analytic and comparative cohorts. Continuous variables were analyzed using means and standard deviations and medians and interquartile ranges for normally and non-normally distributed variables, respectively. Counts and frequencies were used for categorical variables. Chi Squared and Fisher's Exact statistical tests were utilized for categorical variable analysis. Differences between PSA, PSAD and % change in PSA were analyzed using Mann-Whitney-U test for non-normally distributed variables. For patients in the analytic cohort, we analyzed the proportion of patients being diagnosed with prostate cancer and clinically significant prostate cancer by our previously defined PSA and PSAD groups. Graphs were created to better visualize these relationships. Statistical tests were all performed two-sided with significance of p < 0.05. IBM SPSS Version 24 software was used to perform statistical analyses.
Results:
Patient Cohort and Pre-HoLEP characteristics:
Overall, 1202 men with history of HoLEP at our institution between 1999 and 2018 had post-HoLEP PSA data for analysis. Fifty-five men of this large cohort subsequently underwent TRUS biopsy of the prostate and make up the analytic cohort. The remaining 1,147 patients make up the comparative cohort.
Patient demographic and clinical characteristics stratified by analytic and comparative cohort are shown in Table 1 . The mean PSA value prior to HoLEP was slightly lower in the analytic cohort (7.72 vs 8.06, p = 0.831). Prostate volume (p=0.189) and PSA densities (p= 0.401) were similar in the analytic and comparative cohort, respectively. The predominant indication for HoLEP was debilitating LUTS in both cohorts. Only two patients were diagnosed with prostate cancer (both GGG 1) prior to HoLEP.
HoLEP and post-HoLEP data:
Outcomes after HoLEP are depicted in Table 2 . One-hundred forty-seven men (12.2%) were diagnosed with prostate cancer after HoLEP. The analytic cohort was enriched with patients with prostate cancer compared to the comparative cohort (40 vs 10.9%, p < 0.001). A subgroup analysis of the analytic cohort is available in supplementary table 1.
The median PSA after HoLEP was significantly higher (1.60 vs 0.68, p < 0.001 and PSA reduction significantly less (47.2 vs 77.8, p < 0.001) in the analytic cohort.
Analysis of the Analytic Cohort:
Fifty-five men underwent a TRUS biopsy at a median of 18.5 months after HoLEP. Indications for biopsy were rising PSA (46, 84%) or prostate cancer surveillance (9, 16%). PSA prior to biopsy ranged from 0.22 to 52.36 ng/mL. Individual PSA values prior to HoLEP were slightly higher than PSA values prior to biopsy (7.72 vs 6.23, p=0.265). Individual patient's PSAD prior to HoLEP was significantly lower than PSAD values prior to biopsy (0.084 vs 0.210, p<0.001). Overall, 50 (90.9%) patients biopsied after HoLEP were found to have prostate cancer. Fortyone (74.5%) patients biopsied were found to have clinically significant prostate cancer. Fourteen (25.4%) patients biopsied were diagnosed with high risk prostate cancer, Gleason Grade Group 4 and higher. A breakdown of post-HoLEP biopsy results is shown in Table 3 .
There was a strong association between PSA and PSAD prior to TRUS biopsy and primary and secondary outcomes. In the HoLEP cohort, 94% of patients with a PSA above 1 at biopsy were found to have prostate cancer. Furthermore 80% of patients with a PSA above 1 at biopsy had clinically significant cancer. All patients with a PSA following HoLEP greater than 5.8 were diagnosed with prostate cancer. In Figure 1 the results of prostate cancer detection stratified by
A C C E P T E D U N E D I T E D M A N U S C R I P T
PSA prior to biopsy are illustrated. A PSA greater than 4 at the time of biopsy was associated with over 90% probability of Gleason Grade Group 2 or higher cancer. Figure 2 displays the results of biopsy stratified by PSA density. As PSAD rose above 0.15 ng/mL 2 , men in this cohort harbored over a 90% probability of Gleason Grade Group 2 or higher cancer. Overall men with a PSAD greater than 0.1 in this study had a 95% probability of malignancy and an 88% risk of clinically significant disease.
Discussion:
The ability of PSA to distinguish between clinically significant prostate cancer and benign prostatic hyperplasia, especially in treatment-naïve men with large glands, is poor. This study demonstrates the unique positive predictive value of PSA and PSAD as biomarkers for prostate cancer in men who have had the majority of their transition zone removed after HoLEP. Over 90% of our cohort biopsied following HoLEP were found to have prostate cancer and 75% harbored clinically significant disease. When stratifying by PSA and PSAD, we observed a direct correlation between increasing biomarker values and risk of clinically significant disease. In fact, all men with PSA values greater than 5.8 and PSAD greater than 0.17 had biopsy proven prostate cancer. We believe this data has critical implications in the post-HoLEP monitoring of patients by referring physicians.
Other groups have investigated the association between PSA after treatment for BPH and detection of prostate cancer. Elmansy et al. evaluated 355 men who underwent HoLEP over an 8-year period at one center who had complete PSA data prior and after surgery. The group demonstrated that compared to patients who did not develop prostate cancer, the nine men found to have malignancy had significantly higher baseline PSA (9.46 v. 5.44, p=0.032), post-HoLEP PSA (5.83 v. 0.91, p<0.001) and significantly lower PSA % reduction following surgery (47.49 v. 75.39%, p<0.001) 12 . Similarly, men in our cohort diagnosed with cancer during followup demonstrated elevated PSAs and lower PSA % reductions post-HoLEP. In a second study, Helfand et al. retrospectively evaluated 525 men who underwent BPH treatment by a variety of methods (TURP, HoLEP, and Open Prostatectomy). Results demonstrated that men diagnosed with prostate cancer following surgery had higher post-procedural PSA (3.1 v. 1.3, p <0.01) and more quickly rising PSA velocity during follow-up (0.42 v. 0, p <0.01) 13 . The results of these previous studies coupled with our current results suggest that physicians should closely monitor men who do not have a substantial reduction in PSA post-HoLEP. While previous studies have evaluated post-procedure PSA velocity as a marker for prostate cancer, we focused on PSA and PSAD which are more readily available and easier to calculate and interpret.
We believe these have two important and practical implications in the management of men with elevated PSA prior to and after transurethral procedures for LUTS. First, with a mean time from HoLEP to biopsy of 18.5 months, it can be assumed the majority of men in our cohort had clinically significant prostate cancer at the time of HoLEP. Although only 13% of our analytic cohort had pre-HoLEP biopsy data available for review, the majority of them (71%) did not have a previous diagnosis of prostate cancer. Although this may be related to insufficient data from outside urologists, these findings call into question the adequacy of traditional TRUS biopsy in men with elevated PSA and large glands. The results of the PRECISION randomized control trial suggested that MRI-targeted biopsy was superior to TRUS biopsy in the diagnosis of clinically significant prostate cancer in a biopsy-naïve population 14 . We believe these results are pertinent in men with large glands at high risk of sampling error. Performing an MRI and subsequent targeted biopsy may be the most prudent management strategy in men considering BPH surgery in which the diagnosis of clinically significant prostate cancer would change management. This is especially true given the large percentage (33, 66%) of men who eventually underwent primary prostate cancer therapy in our cohort which may be subject to inferior functional outcomes 15 . Second, in the post-procedural period, providers should proceed with caution in men who have elevated PSA and PSAD. Using our data, a conservative threshold of PSA of 1 and PSAD of 0.1 would lead to biopsy for 41 men and allow for the diagnosis of 95% of men with clinically significant prostate cancer with only a small percentage (5%) of men undergoing unnecessary biopsy. Regardless of the most appropriate threshold for biopsy, our primary argument remains. We believe that referring physicians should be aware of improved PPV of PSA and PSAD in men after HoLEP and consider them for biopsy at lower thresholds than treatment-naïve men.
The results of this study should be considered in the context of certain limitations. The inherent biases of a single institutional retrospective study are well known. Despite this, our cohort is the largest study investigating the association between PSA and prostate cancer risk in a cohort of men after HoLEP. Second, men in our cohort underwent prostate biopsy based on the clinical decision of a urological surgeon. Thus, selection bias may have been introduced as patients who did not undergo biopsy were not analyzed and compared to our cohort. However, because a PSAD > 0.1 ng/mL 2 would typically prompt biopsy, we feel this threshold in men with previous HoLEP is a sound benchmark. Third, given our position as a tertiary referral center, many patients undergoing HoLEP were referred from outside practices and never received follow up at our institution. This made obtaining post-HoLEP PSA values impossible in many instances. Moreover, it is possible that some of these men underwent biopsy after HoLEP locally and were not captured in our current study. Therefore, our analysis may underestimate the number of patients who qualified for or underwent a biopsy.
These limitations notwithstanding, we believe the data presented here provides useful evidence for managing men following HoLEP surgery. There appears to be a direct correlation between increasing post-HoLEP PSA and PSA density with likelihood of prostate cancer. Ultimately, a multi-institutional collaboration with other tertiary referral centers who routinely perform HoLEP will be necessary to validate these initial findings. Additionally, assessment of accuracy of biopsy results in relation to prostate gland size may provide an additional layer of evidence for future practitioners. 
